89bio, Inc. ETNB
Institutional shares held
156 Million
774K
calls
6.48M
puts
Total value of holdings
$2.32B
$11.5M
calls
$96.2M
puts
Market Cap
$690M
46,484,500
Shares Out.
Institutional ownership
336.1%
# of Institutions
236
We take great care to ensure that the data presented and summarized in this overview for 89bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETNB
View all-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million5.01% of portfolio
-
Pentwater Capital Management LP Naples, FL11.8MShares$174 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.36MShares$139 Million4.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.1MShares$135 Million0.22% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.28MShares$123 Million3.65% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.05MShares$120 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$104 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.39MShares$94.8 Million1.28% of portfolio
-
Glazer Capital, LLC New York, NY5.64MShares$83.7 Million2.78% of portfolio
-
Janus Henderson Group PLC London, X05.38MShares$79.8 Million0.04% of portfolio
Latest Institutional Activity in ETNB
Top Purchases
Top Sells
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Transactions at ETNB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 30
2025
|
Ra Capital Management, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
19,889,683
-100.0%
|
-
|
|
Oct 30
2025
|
Michael R Hayden |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
165,516
-100.0%
|
-
|
|
Oct 30
2025
|
Michael R Hayden |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
80,904
-100.0%
|
-
|
|
Oct 30
2025
|
Ryan Martins Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
374,295
-100.0%
|
-
|
|
Oct 30
2025
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+8.55%
|
-
|
|
Oct 30
2025
|
Charles Mc Wherter |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,000
-100.0%
|
-
|
|
Oct 30
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
934,273
-100.0%
|
-
|
|
Oct 30
2025
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+11.8%
|
-
|
|
Oct 30
2025
|
Quoc Le Nguyen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
13,694
-100.0%
|
-
|
|
Oct 30
2025
|
Quoc Le Nguyen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
351,684
-100.0%
|
-
|
|
Oct 30
2025
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+12.45%
|
-
|
|
Oct 30
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
352,656
-100.0%
|
-
|
|
Oct 30
2025
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+12.42%
|
-
|
|
Oct 30
2025
|
Francis Willard Sarena Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,310
-100.0%
|
-
|
|
Oct 22
2025
|
Ryan Martins Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,799
+9.89%
|
$242,397
$3.78 P/Share
|
|
Aug 05
2025
|
Francis Willard Sarena Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,979
-3.86%
|
$26,811
$9.69 P/Share
|
|
Aug 01
2025
|
Francis Willard Sarena Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,206
-3.99%
|
$28,854
$9.16 P/Share
|
|
Aug 01
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,680
-2.94%
|
$69,120
$9.16 P/Share
|
|
Aug 01
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,680
-2.47%
|
$69,120
$9.16 P/Share
|
|
Aug 01
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Indirect |
522
-3.67%
|
$4,698
$9.16 P/Share
|
Last 12 Months Summary
Buy / Acquisition
6.81M
Shares
From
9
Insiders
| Open market or private purchase | 5.74M shares |
|---|---|
| Grant, award, or other acquisition | 981K shares |
| Exercise of conversion of derivative security | 80.8K shares |
Sell / Disposition
22.7M
Shares
From
17
Insiders
| Sale (or disposition) back to the issuer | 19.9M shares |
|---|---|
| Disposition due to a tender of shares in a change of control transaction | 2.37M shares |
| Payment of exercise price or tax liability | 158K shares |
| Grant, award, or other acquisition | 285K shares |
| Open market or private sale | 36.8K shares |